Atosiban

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985. Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.

Properties:
Appearance & Physical State: solid
Density: 1.254 g/cm3
Boiling Point: 1469ºC at 760 mmHg
Flash Point: 842.2ºC
Refractive Index: 1.549

Related Prodcuts:

Icatibant; Lanreotide; Nesiritide; Leuprolide Acetate; Liraglutide; Lypressin; Oxytocin; Pasireotide; Bivalirudin; Pramlintide Acetate; Calcitonin Salmon; Alarelin Acetate; Sincalide; Somatostatin Acetate; Glucagon HCl

[1]. Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9.

[2]. Akerlund M, et al. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin. Acta Obstet Gynecol Scand. 1985;64(6):499-504.